Search research articles
Contact Us
Filters
Showing results (481-490 of 491) with videos related to
Page
of 50
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2020
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Neelima Vidula, Taronish Dubash, Michael S Lawrence, et al.
Molecular Cell
|
October 8, 2021
NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer
Hongshan Guo, Gabriel Golczer, Ben S Wittner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Science Translational Medicine
|
July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana
Roger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.
Journal of Medicinal Chemistry
|
April 17, 2008
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential
Saleem Ahmad, Cort S Madsen, Philip D Stein, et al.
Blood
|
December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Science Translational Medicine
|
September 20, 2019
Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in <i>Plasmodium falciparum</i>
Joost Schalkwijk, Erik L Allman, Patrick A M Jansen, et al.
Page
of 50
Search research articles
Search
Showing results (481-490 of 491) with videos related to
Sort By:
Page
of 50
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2020
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Neelima Vidula, Taronish Dubash, Michael S Lawrence, et al.
Molecular Cell
|
October 8, 2021
NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer
Hongshan Guo, Gabriel Golczer, Ben S Wittner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Science Translational Medicine
|
July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana
Roger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.
Journal of Medicinal Chemistry
|
April 17, 2008
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential
Saleem Ahmad, Cort S Madsen, Philip D Stein, et al.
Blood
|
December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Science Translational Medicine
|
September 20, 2019
Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in <i>Plasmodium falciparum</i>
Joost Schalkwijk, Erik L Allman, Patrick A M Jansen, et al.
Page
of 50